昌吉市打掉孩子那家医院好(昌吉包皮过长手术要住院) (今日更新中)

SAN FRANCISCO, April 22 (Xinhua) -- Apple and Google collect smartphone users' location information as part of their race to build massive databases, The Wall Street Journal reported on Friday after analyzing data and documents.According to the report, security analysts with the newspaper found that Apple's iPhone and smartphones running Google's Android operating system regularly transmit users' locations back to the two companies respectively, which is part of their race to build databases capable of pinpointing people's locations via smartphones.A report by research firm Gartner indicated that the market for location-based services is expected to rise to 8.3 billion U.S. dollars in 2014 from the current 2.9 billion dollars.In the case of Google, a security analyst with The Wall Street Journal said an HTC Android phone collected name, location, signal strength of any nearby Wi-Fi networks, and a unique phone identifier every few seconds and transmitted the data to Google at least several times an hour."All location sharing on Android is opt-in by the user," Google said in a statement to technology blog site All Things Digital, in response to the concern that how Android system uses location information."We provide users with notice and control over the collection, sharing and use of location in order to provide a better mobile experience on Android devices. Any location data that is sent back to Google location servers is anonymous and is not tied or traceable to a specific user," said the statement.Worries on the iPhone tracking issue surfaced on Wednesday after two British researchers announced at a technology conference in California that iPhone has been collecting users' location information and storing the data for extended periods of time.The researchers said starting on June 21 2010, after the release of iOS 4 mobile operating system, iPhones began logging and storing location information in a file, which shows the users' latitude and longitude and is timestamped to the second. They noted the information is not encrypted on the phone or on the iPhone backups made by iTunes and the file is also persistent, transferring itself to a new iOS device when the old one is replaced.They added they had no evidence that the file was being transmitted to Apple.On Thursday, U.S. congressman Edward Markey reacted angrily to the news in a letter to Apple CEO Steve Jobs, which is posted on Markey's official website.Markey asked Jobs to make a response within 15 business days or no later than May 12, saying "Apple needs to safeguard personal location information of its users to ensure that an iPhone doesn't become an iTrack."Apple has made no comment on the issue so far, but a letter it sent to U.S. Congress last July came under spotlight. In the letter, Apple said it collects Wi-Fi and GPS information when the phone is searching for a cellular connection and gathers the data to help build a "database with known location information."

WASHINGTON, March 4 (Xinhua) -- New data suggest that the epilepsy drug Topamax (topiramate) and its generic versions increase the risk for the birth defects cleft lip and cleft palate in babies born to women who use the medication during pregnancy, the U.S. Food and Drug Administration (FDA) said Friday in a statement.Before prescribing topiramate, approved to treat certain types of seizures in people who have epilepsy, health care professionals should warn patients of childbearing age about the potential hazard to the fetus if a woman becomes pregnant while using the drug, the FDA said.Topiramate also is approved to prevent migraine headaches, but not to relieve the pain of migraines."Health care professionals should carefully consider the benefits and risks of topiramate when prescribing it to women of childbearing age," said Russell Katz, director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research. "Alternative medications that have a lower risk of birth defects should be considered."Cleft lip and cleft palate, collectively called oral clefts, are birth defects that occur when parts of the lip or palate do not completely fuse together early in the first trimester of pregnancy, a time when many women do not know they are pregnant.The defects range from a small notch in the lip to a groove that runs into the roof of the mouth and nose, possibly leading to problems with eating, talking, and to ear infections. Surgery often is performed to close the lip and palate and most children do well after treatment.Data from the North American Antiepileptic Drug (AED) Pregnancy Registry indicate an increased risk of oral clefts in infants exposed to topiramate during the first trimester of pregnancy. Infants exposed to topiramate as a single therapy experienced a 1.4 percent prevalence of oral clefts, compared with a prevalence of 0.38 percent - 0.55 percent in infants exposed to other antiepileptic drugs.Infants of mothers who did not have epilepsy and were not being treated with other antiepileptic drugs had a prevalence of 0.07 percent. Similar data from the United Kingdom Epilepsy and Pregnancy Register supported the North American AED Pregnancy Registry data.According to the FDA, before starting topiramate, pregnant women and women of childbearing potential should discuss other treatment options with their health care professional.

BEIJING, Feb. 5 (Xinhua) -- China's railways transported about 77.34 million passengers during the fifteen days (Jan. 19 to Feb. 2) before the Spring Festival, the Ministry of Railways said.The figure was about 9.5 percent higher than the same period last year and set a new record, according to a report posted on the ministry's website.There were an average of 5.16 million passengers per day, up 448,000 from the same period last year. On Jan. 29, passengers topped 5.78 million, setting a new record for daily transportation before the Spring Festival, the report said.In the fifteen days before the festival, about 4.80 million passengers left Beijing, 8.39 million left Guangzhou and 5.69 million left Shanghai, while year-on-year growth and those leaving Guangzhou rose the most, up 15 percent year on year, said the report.The ministry said challenges still exist as more snow and rain will hit southern China after the Spring Festival, when passengers are returning.China's busy Spring Festival transportation season runs for 40 days and is calculated in two phases: 15 days before the Spring Festival and 25 days after the Spring Festival, the report explained.

BRASILIA, April 26 (Xinhua) -- A survey conducted by Brazil's Ministry of Health showed Tuesday that half of Brazilians aged over 55 have hypertension.According to the research, which has been carried out annually since 2006, the proportion of Brazilians diagnosed with hypertension increased over the past five years, from 21.6 percent in 2006 to 23.3 percent in 2010.Besides, the diagnosis of hypertension is higher among women (25.5 percent) than men (20.7 percent). But in both sexes, the older people are, the more common the disease becomes, the ministry reported.The ministry also said that, to address the problem, the Brazilian government distributes free medicines to control blood pressure, since 80 percent of Brazilians who suffer from hypertension depend on the public health system.The Ministry of Health signed on April 7 an agreement with the food industry, aiming to reduce salt in processed food.If hypertension is left untreated, some complications including clogged arteries, stroke and myocardial infarction will bring patients more troubles.

WASHINGTON, April 11 (Xinhua) -- In the first clinical trial of gene therapy for treatment of intractable pain, U.S. researchers from the University of Michigan's Department of Neurology observed that the treatment appears to be able to provide substantial pain relief.In a study published online in the Annals of Neurology and seen on Monday, the researchers showed that the novel agent NP2 is safe and well-tolerated. In addition, measures of pain in the treated patients suggested that NP2 may provide a substantial analgesic effect.NP2 is a gene transfer vector that expresses the naturally- occurring opioid peptide enkephalin. In preclinical work in animals, David Fink, chair of the Department of Neurology, and his coworkers had demonstrated that injection of NP2 into the skin reduces pain in models of pain caused by nerve damage, inflammation or cancer.In the clinical trial, 10 patients with unrelenting pain caused by cancer were injected with the gene transfer agent in the area of skin related to the location of pain."The concept underlying this therapeutic approach is that injection of NP2 into the skin results in uptake into the nervous system and the production and release of a pain-relieving chemical in a controlled site in the pain pathway," says Fink. "In the study, patients who received the low dose of vector showed little reduction in pain; patients receiving the higher doses showed a greater than 80 percent reduction in pain over the course of four weeks following treatment."Fink's laboratory has been working on the use of modified herpes simplex virus-based vectors that are taken up by sensory nerves following skin injection to develop therapies for diseases of the nervous system for more than 20 years. Patents related to this technology have been exclusively licensed by Diamyd Medical, a publicly-traded Swedish biotechnology company that sponsored the trial, and the human-grade vector NP2 was produced by Diamyd, Inc, the U.S. subsidiary of Diamyd Medical.A phase 2 trial to compare NP2 to a placebo control has already been initiated under sponsorship from Diamyd.

来源：资阳报